SEGMENT REPORTING

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

SEGMENT REPORTING

NOTE 17 – SEGMENT REPORTING

Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment.

The Company classifies its business interests into reportable segments which are:

● Trxade, Inc. - Web based pharmaceutical marketplace platform – B2B sales

● IPS - Integra Pharma, LLC - Licensed wholesaler of brand, generic and non-drug products – B2B sales

● Superlatus – holds Sapientia’s intellectual property for advanced food extrusion technology and The Urgent Company – Manufacturer of ice cream that is animal product-free, vegan, lactose-free, and made with plants – B2B sales

● Unallocated - Other – corporate overhead expense, discontinued operations and Bonum Health, LLC.

Nine months ended September 30, 2023	Trxade, Inc.		IPS			Superlatus			Unallocated			Total
Revenue	$	4,663,756	$	1,237,731		$	-		$	18,299		$	5,919,786
Gross Profit		4,663,756		165,553			(756	)		18,299			4,846,852
Segment Assets		-		-			18,029,077			3,624,766			21,653,843
Segment Profit (Loss)		1,570,796		(388,900	)		(440,268	)		(6,869,237	)		(6,127,609	)
Cost of Sales		-		1,072,178			756			-			1,072,934

Nine months ended September 30, 2022	Trxade, Inc.		IPS			Superlatus		Unallocated			Total
Revenue	$	4,001,670	$	3,949,772		$	-	$	42,363		$	7,993,805
Gross Profit		4,001,670		(41,462	)		-		42,363			4,002,571
Segment Assets		1,853,474		454,783			-		2,172,060			4,480,317
Segment Profit (Loss)		1,320,138		(493,203	)		-		(3,433,774	)		(2,606,839	)
Cost of Sales		-		3,991,234			-		-			3,991,234